Sutro Biopharma announced that it has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to use Sutro's proprietary cell-free protein synthesis technology to produce bispecific antibodies that were discovered by Memorial Sloan-Kettering for the treatment of neuroblastoma in children. Under the collaborative agreement Sutro will use its cell free protein synthesis technology to produce four different bispecific antibodies discovered by Memorial Sloan-Kettering. These antibodies will be directed against CD3 on T-cells and, as the second target, against the ganglioside GD2, which is expressed on the surface of human neuroblastoma cells, as well as in melanoma and osteosarcoma.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.06 USD | -0.25% |
|
+12.78% | -5.36% |
Jul. 16 | Indices: What's small becomes cute again | ![]() |
Jul. 09 | Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.36% | 333M | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |
- Stock Market
- Equities
- STRO Stock
- News Sutro Biopharma, Inc.
- Sutro Biopharma to Collaborate with Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma